DCK is an Unfavorable Prognostic Biomarker and Correlated With Immune Infiltrates in Liver Cancer
DCK is an Unfavorable Prognostic Biomarker and Correlated With Immune Infiltrates in Liver Cancer
复制标题
DOI：
10.1177/1533033820934133
复制
发表时间：
2020-06-25
影响因子：
2.8
通讯作者：
Jin, Li
中科院分区：
文献类型：
--
作者：
Hu, Shu Fang;Lin, Xia;Jin, Li
背景：脱氧胞苷激酶在肿瘤中的生物学功能尚不清楚，目前关于脱氧胞苷激酶基因与肝癌发生发展相关性的研究较少。方法：采用UALCAN和GEPIA数据库分析脱氧胞苷激酶信使RNA的表达。此外，我们利用Kaplan-Meier绘图数据库评估脱氧胞苷激酶对临床预后的作用。通过肿瘤免疫评估资源网站研究脱氧胞苷激酶与肿瘤免疫浸润的关系。此外，我们还利用肿瘤免疫估计资源（Tumor Immune Estimation Resource）来评估脱氧胞苷激酶表达与免疫浸润基因标记集的相关性。结果：肝癌患者脱氧胞苷激酶信使RNA水平较正常肝脏明显上调。此外，脱氧胞苷激酶信使RNA的表达增加与所有肝癌的总生存期和无病生存期的降低密切相关。此外，脱氧胞苷激酶的表达与肝癌中巨噬细胞、中性粒细胞和树突状细胞的浸润水平有很强的相关性，脱氧胞苷激酶的表达与肝癌中多种免疫标记物的表达呈正相关。结论：上述结果提示肝癌患者脱氧胞苷激酶表达升高与预后不良有显著关系。脱氧胞苷激酶与肝癌患者的免疫浸润水平相关，包括B细胞、巨噬细胞、中性粒细胞和树突状细胞。这些结果提示脱氧胞苷激酶可作为肝癌预后和免疫浸润的预后生物标志物。而脱氧胞苷激酶是肝癌治疗的潜在靶点，这些初步发现还需要进一步研究，以确定是否可以开发脱氧胞苷激酶靶向试剂用于肝癌的临床应用。
Background: The biological function of deoxycytidine kinase in tumor is not yet clear, and there are a few studies relating to the correlation of deoxycytidine kinase gene with the occurrence and development of liver cancer. Methods: The messenger RNA expression of deoxycytidine kinase was analyzed with the use of the UALCAN and GEPIA database. Moreover, we assessed the function of deoxycytidine kinase on clinical prognosis with Kaplan-Meier plotter database. The relationship between deoxycytidine kinase and cancer immune infiltrates was investigated via Tumor Immune Estimation Resource site. Furthermore, Tumor Immune Estimation Resource was also used to evaluate the correlations between the expression of deoxycytidine kinase and gene marker sets of immune infiltrates. Results: The deoxycytidine kinase messenger RNA level significantly upregulated in patients with liver cancer compared to normal liver samples. Moreover, the increased expression of deoxycytidine kinase messenger RNA was closely associated with reduced overall survival and disease-free survival in all liver cancers. In addition, deoxycytidine kinase expression displayed a strong correlation with infiltrating levels of macrophages, neutrophils, and dendritic cells in liver cancer, and deoxycytidine kinase expression was positively correlated with diverse immune marker sets in liver cancer. Conclusions: All the above findings suggested that increased expression of deoxycytidine kinase was significantly related to unfavorable prognosis in patients with liver cancer. And deoxycytidine kinase is correlated with immune infiltrating levels, including those of B cells, macrophages, neutrophils, and dendritic cells in patients with liver cancer. These findings suggest that deoxycytidine kinase can be used as a prognostic biomarker for determining prognosis and immune infiltration in liver cancer. And deoxycytidine kinase is a potential target for liver cancer therapy, and these preliminary findings require further study to determine whether deoxycytidine kinase-targeting reagents might be developed for clinical application in liver cancer.